Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Operating Expenses (2016 - 2025)

Abeona Therapeutics has reported Operating Expenses over the past 15 years, most recently at $28.3 million for Q4 2025.

  • Quarterly results put Operating Expenses at $28.3 million for Q4 2025, up 69.93% from a year ago — trailing twelve months through Dec 2025 was $95.3 million (up 48.37% YoY), and the annual figure for FY2025 was $95.3 million, up 48.37%.
  • Operating Expenses for Q4 2025 was $28.3 million at Abeona Therapeutics, up from $24.0 million in the prior quarter.
  • Over the last five years, Operating Expenses for ABEO hit a ceiling of $49.7 million in Q4 2021 and a floor of $9.0 million in Q2 2022.
  • Median Operating Expenses over the past 5 years was $14.7 million (2021), compared with a mean of $17.8 million.
  • Biggest five-year swings in Operating Expenses: surged 184.05% in 2021 and later plummeted 73.81% in 2022.
  • Abeona Therapeutics' Operating Expenses stood at $49.7 million in 2021, then plummeted by 73.81% to $13.0 million in 2022, then grew by 1.58% to $13.2 million in 2023, then grew by 26.22% to $16.7 million in 2024, then surged by 69.93% to $28.3 million in 2025.
  • The last three reported values for Operating Expenses were $28.3 million (Q4 2025), $24.0 million (Q3 2025), and $23.2 million (Q2 2025) per Business Quant data.